Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I`M BACK - GOOOOOOOOOOOOOOOOOO CYDY GOOOOOOOOOOOOOOOOOOOO AMERICA!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I’m trying not to embarrass you, go look at post 232432, can you read where you said by July 1, not July 4, so tell me Grip, who can’t read, get a calendar dupe
You are truly a fool! I’m embarrassed that I have to respond to such nonsense but here we are.
Want to clarify because you clearly have trouble reading.
The bet was JULY 4! Get a calendar!
Wow, you trying to justify your loss is hilarious, and for the record, I was never a big Nader fan, don’t forget Friday dupe
If you’re gonna spew bullshit, try to be believable for once!
The fact that you’re excited that this is $.03 away from a dime is phuckin funny.
Also, go back and check my history! I sold on the $4’s! I made alot of money on this trash!
You want to know why?
1) I called out Nader as a fraud loooong before many did and cashed out
2) I identified dupes like you during the Nader pump calls to help me flip it often
3) I knew when to exit for final time
You: “yeah, made some extra money and averaged down” hahahaha
Now that you’re nearly at all-time low and Jay Jay just rammed up your prune chute with a $.09 offering, how to expect to get out of this? You can’t!!
Enjoy the day! Lots to do today:.::
So what, you will not be here to cry anymore, you say the company is shit but you invested in it and lost your money, we get it, you are bitter and should have diversified some money
Maybe! But whether it happens in four days or forty days, this company is shit and in life support!
But if it touches $.10 this week, delete your account! Did you notice the fake pump yesterday! Just teeing it up for major dump!
And we have seen for years the heartache you have been through, you make no difference here, none, and always so mad
Checks ticker- $.1375!
We agree, spot on! Give us some more fiction. You’re always good for a laugh with your tall tales
keep going weirdo.you're 100 percent spot on
What the hell does that have to do with leronlamoob??? Huh????
Um, "brother" from ymb, my little dumb middle eastern rider of spitting mammals that cant spell mandatory correctly friend, wait for the PR?
Hmmm, let me see, for years its been "wait for this", "wait for that", "wait for the PR", "wait for the arrests," "coming soon", "youll see", "Im calling the cops", all the while the stock has free fallen to the teens and soon single digits.
Stop being an idiot and read the filings. Looks like the CEO said hes willing to settle for 9 cents and from the looks of its just a matter of time when that becomes 5 cents and less.
We all see your pain, youve even admitted right here on this message board you are hurt, Im just here to pour salt into ones wounds.
LAUGHING
{off topic}
In the U*.S. over 1,500,000 persons died of covid-19 from start to now. Most of them were injected and booster shots twice or more. Many of the survivors have or had side effects. I was one of them with side effects and had to go twice to to the ER or emergency at my hospital.
What happened, at night about 2o`clock I woke up with feelings of vomiting, when I tried to get up, I collapsed to my knees, then crawled to the bath room, vomited with nothing coming out for about 3 minutes. That takes a lot of energy. After a while, I was able to pull myself up to the sink and drank some water and then *I was able to walk back to bed. Wen I woke up that morning, I felt like nothing ever happened that night. This was going on for about 6 month, with interewells of 1 or two weeks.
the Biden admin made it manditory and caused many to die from it. Right?
Wrong. It was only mandatory (note correct spelling) for employees of the federal government. And very, very few people have died, although the vaccines have been administered to more than 230,637,348 people in the U.S.
https://usafacts.org/visualizations/covid-vaccine-tracker-states/
Um, dumdum/"brother", this "dog" that's up 24 percent today, how did that pan out?
Firsthand Funds-Technology Opportunities Fund is at 233K shares, Grip, I think you need to get a hold of the managers there and give them a bit of your wisdom and financial insights. I mean, you know, you don't want to see people lose money on this "dog" that's up 24 percent today.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174502573
At least Trump made it an option to be vaccinated- the Biden admin made it manditory and caused many to die from it. Right?
Stay on topic, bot!
BTW- your favorite orange FORMER president was jabbed! Actually it was his administration that brought the vaccine:
Don’t blame Fauci! The president is the leader! So which is it? Trump loves the vaccine or wasn’t really in control? Pick one
oh how hilarious the pigeon back patting. Great leaders! The numbskulls mimic their paymasters who got us into this overkill in the first place.
" The mainstream media continues to be the source of extensive media disinformation.
It sustains the lies concerning the Covid crisis and the mRNA vaccine, which has resulted in an upward trend of excess mortality." Global Research, June 25, 2024
Strange they don't like saving lives. Very strange indeed. Nice to see the pendulum swinging too. Yippers, going to be a nice payday in more ways than one.
2024 will go down in history as the comeback year for leronlimab and finally the process will begin again. Patience pays great dividends.
Quite pleased with our CEO. Their hard work was undetected by pigeon brains all the while preparation of the immense load of redundant fda requirements were met and conquered. Well done Dr. Jay. A team effort where now offers are pouring in for collaboration. Leronlimab is that good. And safe!
Hey pigeons, are you boosted and jabbed to the max yet? Get er done feathered friends. We will be taking out the trash soon so don't fly off... that is if you can still get airborne. $CYDY$ 2024 Gentlemen, start your engines.
Bravo on the face plants you post! The day you posted this was a weekend. In the beginning of the week it was $.25. It’s now $.13-.14, headed to the company adjusted offering of $.09
Ironically, while you think you’re “owning” bashers you’re subconsciously truthful, just not in a way you intended.
Have you noticed that most of the mouthpieces on this board screaming “partnerships”, “trials” “approvals” etc have left! Why is that! Because they know they just took it straight in the ars!
Thanks for playing! Please adding the pithy commentary: always good for a chuckle between meetings
With excellent board leaders like yourself...we will all be safer investors! Your incredible advice on your stock board is A+ !
The actions of Nader and Scott dumping their shares when it was priced at a measly $3 and change in 2020 should've informed the lololongs what the insiders thought about the wonder drug. They didn't wait for any buyouts or the price to rise to $100, no they sold out for chump change. But the longs believed Nader's bullshit about selling shares to save the company. If that were the case the company would have had to disclose that in the filings, but of course it never did because the company didn't receive a cent from Nader enriching himself!
Do we need to say outwardly how fundamentally stupid this post is? Point to a single “certainty” the company has. Any sentence that doesn’t contain “hope”, “anticipate”, “believe” and “near future”! Hysterical!
They just showed you last week what they value their own company at! $.075
We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease,
BEWARE SHORTY,,,,,BRIEF-Spectral AI Provided Support To Nasdaq And State Securities Authorities To Bring To Attention "Potential Market Manipulation"
HERE IS WHAT I LIKE EVEN MORE... FROM OUR COMPANY UPDATE A FEW WEEKS AGO
Research and development partnership opportunities are important to the Company as we search for cost-effective ways to further build out our product development portfolio. We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease, and a project that will evaluate the use of leronlimab in patients living with HIV who are undergoing stem cell transplantation in a proof of cure study. Following lifting of the clinical hold, we have observed a significant increase in third parties that are interested in partnering with the Company. We will continue to review opportunities as they arise, given the potential for significant value return at little or no cost to the Company.
KEEP ON SHORTIE... $CYDY$ 2024 ah yesm, cheapies luv em. Cheap cheap and gobble gobble.
Thing is I didn't guess it. Your pathetic "joke" makes no sense
Hey NikNak Patty Whack!!
This says a lot about your self/professed “streetology” prowess in investing
You still want to stand by the last sentence? Remember when “we” WARNED you and other baggies? Stupidity isn’t a good look!! Neither are conspiracy theories. Everything you needed to make good decisions was right in front of you! You CHOSE to ignore.
This is why charlatans like the former POTUS, Nader, Jim Jones and Manson can do what they do! They commit crimes in broad daylight while the seals clap them on.
Bravo!
Lolll the Bollinger bands yesssss!!!!!!
And if you read the RTB post (couple days ago / below) and his analysis of the warrants/conversions. Those folks getting the 20% extra shares thrown in--they are paying under 8 cents/share.
We have yet to hear about the bollinger bands, triple digits, Brazil, BLA filing, minimal dilution, broken fax machines, the many partners when holds are lifted, new monkeybutt data
Blue- don’t worry about the bet! The board needs your pragmatic input.
Stay aboard
Your post is fair and factual! Don’t leave, your input even if I may sometimes strongly disagree is always useful.
with the new offering, while the SP hasn't hit $.10, the "market price" has effectively been set at $.09 - at least based on the offering email to convert warrants that I received. To view it as anything other than an act of desperation would be naive.
I signed on to the bet that I would retire from posting if we hit .10 - if anyone wants to push that issue, i'll drop off now and ride off into the sunset - because that's more or less where we are. To Grip and others who called it, well played. Whether we technically hit it or not, who knows. But let's be clear - the real issue isn't whether the stock drops a few more cents to $.10 - the real issue is that this is the last straw - i don't see any other possible source of money for the company after this - so, can they survive on this last gasp of cash. I guess time will tell - but the risk reward has become very poor. I say that because the chance that this company fails due to lack of funds is very high - and the upside scenario at best is making a profit several years down the road, as they don't even have a trial close to starting (and trials take a really long time to enroll, collect data, etc - many years). So again, a very poor risk / reward profile. I've moved most of my biotech money into other plays as a result, but i still watch CYDY - it's like watching the Jerry Springer show.....can't look away.
She is banned until August.
My farts cure more disease than leronlimab
but but Jay Lala is such a good guy and honest man that is why he came back to captain this shipwreck, not to collect on the $400K owed his company for past services rendered.
Goes to show how bad things really are in CYDY la la land.
Looks like they basically cant even give these shares away let alone finding dupes to buy them.
Lets be real, they know just like we do leronsaline is worthless swill, its been tested over and over and over again for at least two decades with millions of dollars spent and the results are always the same....failed to meet endpoints.
8 cent shares will not change the efficacy of leronsaline.
Idiot longs cheer 14 cents LOL what a bunch of losers!!!!
Thx for the breakdown. Its odd to see "others" telling (spin) how this ends the warrant "overhang" / non dilutive/ will fully fund trials
Guess all those "partnerships as soon as hold lifted"--didn't get the memo about funding trials ??
But just you wait--there is 100+ million $$ coming from Amawrecks (they took advantage of poor lil nodder) . Weed/wine told us, so it must be true .
Nice close considering all the expectations of falling to .10!!!
WHAT EVER HAPPENED TO MISIU45?
I miss her posts. They were always interesting with news on Leronlimab.
Another baggie! How we looking after today’s SEC filing?
Damn, it’s almost painful embarrassing you fools. It’s too easy
FINALLY!!!! A post you will be correct on!
Well done, bud!
Laughing!
Two fools yodeling with each other!! You going to accept the results of the bet or renege like Tom?
I said it will hit $.10 by July 4!! You said it wouldn’t. If I’m wrong, I’ll never post again on this board? You took the offer! ‘Nise is already backpedaling.
What say you?? Once you decide, please re-read my prediction and compare the events to Jay-Jay’s pump call and ask yourself who was correct!
Bahahaha! $.09 here we come on way to Chapter 11
Hey Grip: thank heavens i do not make promises. I’ll be here when it hits ten cents and beyond.
Look at these complete morons on reddit!!!! "Several aspects of the SEC filing regarding CytoDyn's warrant exercise offer might hint at the possibility of upcoming positive news or strategic announcements, such as new partnerships or collaborations"
Lollllllllll what's next for these idiots?
"several aspects of the SEC filing regarding CytoDyn's bankruptcy might hint at the possibility of upcoming positive news or strategic announcements, such as new partnerships or collaborations"
Thanks Closet- sounds worse than I read originally.
The 13% vig is unbelievable. What do you suspect with the price action? I suspect it will hit around $.10 within the week but much depends on whether many longs accept the deal and exercise.
The company will be dumping them like hotcakes. This was the logical end result.
Always appreciate your input!
Grip - Per the math in the filing, each share is 7.9, which includes 1 warrant, another .2 shares and more than 13% cash to Paulson!
7.9 cents per unit!
Congrats Gilead! Impressive HIV results! Oh hi CYDY... Yeeeeahhh sorry
Tom- want to revisit this comically desperate gibberish?
Did you read the SEC filing today? If not, let me help you and the others that will be exiting this board this week or next!
Your boy, Jay Jay just sold your broke ass down the river! $.09 (NINE PENNIES) is the new offering price.
Thanks for playing along. Sure you wish you listened. You seem like a nice person but refuse to believe your lying eyes.
BTW- you think MissyMooMoo is pissed she can’t respond within in Hub jail!
Have a great weekend
Followers
|
812
|
Posters
|
|
Posts (Today)
|
13
|
Posts (Total)
|
232988
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |